TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05216432: First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6

Sponsor: Relay Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 930 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT05216432 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05216432 Rescue Dossier →